Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Debiopharm Moves Forward Three of its Oncology Clinical Programs

Published: Thursday, May 29, 2014
Last Updated: Thursday, May 29, 2014
Bookmark and Share
Company will present the recent progresses at the 50th American Society of Clinical Oncology Annual Meeting.

Debiopharm Group™ (Debiopharm) has announced that new data on the investigational compounds Debio 1143 (SMAC mimetic), Debio 1347/CH5183284 (FGFR 1,2,3 inhibitor), and Debio 0932 (Hsp90 inhibitor) will be presented at the 50th American Society of Clinical Oncology (ASCO) Annual Meeting, May 30 to June 3, 2014, in Chicago.

Debio 1143 is an orally available small molecule inhibitor of apoptosis proteins (IAPs) that mimicks the activity of the natural second mitochondrial-derived activator of caspases (SMAC). By targeting IAPs, Debio 1143 can induce cancer cell death and potentiate the efficacy of chemo- and/or radiotherapy. Debio 1143 has been assessed in two phase I clinical studies and two phase I/II trials are ongoing in Europe.

Debio 1347/CH5183284 is a selective oral fibroblast growth factor receptor (FGFR) 1, 2, 3 inhibitor that has shown anti-cancer efficacy in several preclinical animal models in vivo. Debio 1347/CH5183284 will enable personalized treatments and will be developed with a companion diagnostic.

Debio 1347/CH5183284 is currently being evaluated in Europe and USA, in a first-in-man phase I trial in patients with advanced solid tumors displaying alterations of the FGFR 1, 2, or 3 genes.

Debio 0932 is a small oral molecule inhibitor of heat shock protein 90 (HSP90). Inhibition of HSP90 results in the degradation of oncoproteins that drive malignant progression and leads to cell death. Debio 0932 has shown efficacy in various mouse tumor xenografts and exhibits sustained tumor retention.

Debio 0932 has been investigated in one phase I clinical study. Two phase I/II studies are ongoing in Europe in advanced non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC) in combination with SOC and everolimus, respectively.

"We are very pleased to present results of our strong involvement in cancer treatment research and further establish our commitment to this challenging medical field" said Jean-Maurice Dumont, Vice President Medical Affairs". "The ability to relieve people with cancer is an accomplishment".


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Debiopharm and EORTC Announce a Collaboration
Collaboration to investigate triptorelin for treatment of salivary gland cancers.
Thursday, January 14, 2016
Debiopharm and Solid Biosciences Announces Collaboration
Debiopharm to start pre-clinical animal studies in Duchenne Muscular Dystrophy with Solid Biosciences.
Thursday, September 10, 2015
Debiopharm Announces Phase III Positive Results for Triptorelin 6-month Formulation
Triptorelin 6-month formulation phase III trial demonstrates good efficacy in terms of pituitary and gonadal suppression and in arresting or reversing progression of clinical signs of puberty and slowing down of accelerated bone maturation in children with CPP.
Friday, May 22, 2015
Debiopharm Initiates Clinical Phase II Study to Evaluate Debio 1450
One year after the initiation of Phase I, Debiopharm has announced the start of clinical phase II for Debio 1450 in ABSSSI and presentation of new data at ECCMID.
Friday, May 01, 2015
Debiopharm Announces Progress in Phase I Single and Multiple Ascending Dose Study of Debio 1450
Debio 1450 - A highly potent anti-infective agent selectively active against Staphylococcus species.
Wednesday, October 15, 2014
Curis and Debiopharm Report Preclinical Data for Debio 0932
Debio 0932 demonstrated anti-tumor activity and synergy with various SOC agents in in vitro and xenograft models of NSCLC and RCC.
Wednesday, April 09, 2014
Debiopharm to Acquire Affinium’s Antibiotic Clinical Assets and Platform
Company acquire clinical and preclinical assets to identify and develop targeted antibiotics.
Wednesday, February 12, 2014
Debiopharm Announces Completion of Recruitment for Phase III Clinical Study in CPP
Completion of recruitment and results are expected in Q4 2014.
Monday, January 20, 2014
Curis and Debiopharm Announce Initiation of Phase I Dose Finding Study of Debio 0932
Designed to target advanced metastatic renal cell carcinoma, the study will determine the maximum tolerated dose of Debio 0932 in combination with everolimus.
Thursday, October 24, 2013
Debiopharm Initiates Phase I Dose Escalation Study with Debio 1347 (CH5183284)
First clinical phase I study in patients with advanced solid tumors with FGFR alterations.
Tuesday, September 03, 2013
Aurigene and Debiopharm Group™ Report Nomination of Debio 0617B
Debio 0617B is expected to enter clinical development in Q42014.
Monday, July 15, 2013
Shasun Pharmaceuticals and Debiopharm Enter Into Licensing Agreement
Agreement for the manufacturing and commercialization of Huperzine-A.
Wednesday, April 10, 2013
First Patient Treated in Phase III Study with SC Administration of Debio 8206
Administration of Debio 8206 by SC route will prove very convenient in prostate cancer patients.
Thursday, December 27, 2012
Debiopharm Announces First Patient Enrolled in Phase III Study
Phase III study for the rare disease central precocious puberty.
Monday, August 27, 2012
Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of Debio 0932
Company expects to initiate a combination Phase I/II study in NSCLC patients in the second quarter of 2012.
Tuesday, February 21, 2012
Scientific News
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Trying to Conceive Soon After a Pregnancy Loss May Increase Chances of Live Birth
NIH study finds no reason for delaying pregnancy attempts after a loss without complications.
BRCA1 Deficiency Increases the Sensitivity of Ovarian Cancer Cells to Auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Shingles Vaccine Helps Protect Older Patients with End-stage Renal Disease
Kaiser Permanente study advances knowledge about safety and effectiveness of vaccine commonly given to older adults.
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!